# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects

> **NCT05794672** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Healthy Subjects (Indication: Asthma)

## Interventions

- **DRUG:** Elarekibep
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05794672
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-11
- **Primary completion:** 2023-07-08
- **Final completion:** 2023-07-08
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** This decision was based on lung findings from a non-clinical 13-week GLP toxicology study, which are not a concern for the active clinical studies but do not support long-term use and progression to later-stage development.
- **Last updated:** 2023-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05794672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05794672, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05794672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*